tbuckley/cabot-search huggingface dataset:
MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis
Authors: Keisuke Koroki, Sadahisa Ogasawara, Iwanaga Terunao, Hidemi Unozawa, Kisako Fujiwara, Miyuki Nakagawa, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Naoya Kato
Journal: Annals of Oncology (2022)
P69-1 Advantages of using patient-reported outcomes (PROs) during chemotherapy for esophageal cancer
Authors: Tomoki Sakakida, Takeshi Ishikawa, Toshifumi Doi, Ryuichi Morita, Ken Inoue, Akito Harusato, Osamu Dohi, Naohisa Yoshida, Kazuhiko Uchiyama, Tomohisa Takagi, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Hideyuki Konishi, Yoshito Itoh
Journal: Annals of Oncology (2022)
MO25-4 Exploratory analysis of HER2 extracellular domain in HER2-positive gastric cancer treated with SOX plus trastuzumab
Authors: Shuichi Hironaka, Takeru Wakatsuki, Naoki Ishizuka, Keiko Minashi, Shigenori Kadowaki, Masahiro Goto, Hirokazu Shoji, Hidekazu Hirano, Izuma Nakayama, Hiroki Osumi, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, Daisuke Takahari
Journal: Annals of Oncology (2022)
MO29-3 A database of 1023 patients with NSCLC and uncommon EGFR mutations treated with afatinib: focus on Asian patients
Authors: Satoru Miura, Martin Schuler, Sanjay Popat, Keunchil Park, Antonio Passaro, Filippo De Marinis, Flavio Solca, Angela Märten, Edward S. Kim, James Chih-Hsin Yang
Journal: Annals of Oncology (2022)
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
Authors: Kristian Reich, Jacob P Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P Rice, H Chih-Ho Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernan Valdez, Urs Kerkmann
Journal: The Lancet (2022)
MO18-1 Impact of cachexia on survival before first-line chemotherapy for metastatic breast cancer
Authors: Kazuki Nozawa, Ayaka Isogai, Daiki Takatsuka, Yuka Endo, Yuri Ozaki, Nanae Horisawa, Ayumi Kataoka, Haruru Kotani, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Hiroji Iwata
Journal: Annals of Oncology (2022)
MO24-1 Comparison of Nivo-Ipi versus TKIs as first line therapy for mRCC: Real-world data from multicenter retrospective study
Authors: Noriyoshi Miura, Shinsuke Mouri, Akihiro Maeda, Kenichi Nishimura, Yuki Miyauchi, Tadahiko Kikugawa, Sawada Yuichiro, Tomida Ryotaro, Matsumura Masafumi, Hashine Katsuyoshi, Yanagihara Yutaka, Ninomiya Iku, Kan Masaharu, Asai Seiji, Tacho Takatoshi, Saika Takashi
Journal: Annals of Oncology (2022)
MO30-5 Clinicopathological factors affecting prognosis in marginal zone lymphoma in an Asian tertiary cancer centre
Authors: Yao Neng Teo, Yao Hao Teo, Lay Poh Khoo, Esther Wei Yin Chang, Ya Hwee Tan, Jianbang Chiang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Miriam Tao, Soon Thye Lim, Jason Yongsheng Chan
Journal: Annals of Oncology (2022)
MO21-2 Correlation of response following NACT between FDG PETCT and TRG in SCC of esophagus: A prospective study
Authors: Naveen Kumar, Svs Deo, Sandeep Bhoriwal, Amitabh Mondal, Atul Sharma, Raja Pramanik, Rakesh Kumar, Sunil Kumar
Journal: Annals of Oncology (2022)
O12-4 Clinical significance of comprehensive genomic profiling in pediatric cancer patients
Authors: Minako Sugiyama, Junko Kikuchi, Yoshihito Ohhara, Kanako Hagio, Toraji Amano, Emi Takakuwa, C. Kanako Hatanaka, Yutaka Hatanaka, Atsushi Manabe, Takeo Sarashina, Masaki Yamamoto, Yusuke Mizukami, Kohichi Takada, Hirohiro Naruse, Takashi Mitamura, Ichiro Yabe, Akihiro Sakurai, Hirotoshi Dosaka-Akita, Ichiro Kinoshita
Journal: Annals of Oncology (2022)
P52-5 Effort of Cancer Genome Center Hospital in Rural National University
Authors: Yoshinaga Okugawa, Takumi Fujiwara, Takahito Kitajima, Maki Nakamura, Makoto Ikejiri, Takeshi Sasaki, Reiko Yamada, Katsunori Uchida, Ryotaro Hashizume, Hiroshi Imai, Yasutaka Tono, Kanako Saito, Ikuyo Mochiki, Toshiro Mizuno, Yuji Toiyama, Kaname Nakatani
Journal: Annals of Oncology (2022)
MO29-1 The relationship between EGFR variant allele frequency and efficacy of osimertinib in EGFR mutation-positive NSCLC
Authors: Seigo Katakura, Shuji Murakami, Shinada Kanako, Ushio Ryota, Kondo Tetsuro, Kato Terufumi, Yokose Tomoyuki, Saito Haruhiro
Journal: Annals of Oncology (2022)
MO2-2 HGCSG2101: A real-world analysis of nanoliposomal irinotecan plus 5-FU/LV in pancreatic ductal adenocarcinoma
Authors: Masayoshi Dazai, Kazuaki Harada, Takahiro Yamamura, Osamu Muto, Michio Nakamura, Susumu Sogabe, Kentaro Sawada, Masataka Yagisawa, Tetsuhito Muranaka, Shintaro Nakano, Miki Tateyama, Ken Ito, Rika Saito, Yoshimitsu Kobayashi, Sosuke Kato, Takuto Miyagishima, Yasuyuki Kawamoto, Satoshi Yuki, Yuh Sakata, Yoshito Komatsu
Journal: Annals of Oncology (2022)
Identification of 969 protein quantitative trait loci in an African American population with kidney disease attributed to hypertension
Authors: Aditya Surapaneni, Pascal Schlosser, Linda Zhou, Celina Liu, Nilanjan Chatterjee, Dan E. Arking, Diptavo Dutta, Josef Coresh, Eugene P. Rhee, Morgan E. Grams
Journal: Kidney International (2022)
P62-2 Association of survival and tumor marker value fluctuation during CRT in patients with unresectable stage III NSCLC
Authors: Momoko Morishita, Hidehito Horinouchi, Akiko Tateishi, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Yuichiro Ohe
Journal: Annals of Oncology (2022)
P57-3 Factors of the third-line treatment induction in advanced gastric cancer based on eligibility for clinical trials
Authors: Miho Sakumura, Takayuki Ando, Katsuhisa Hirano, Takeshi Miwa, Iori Motoo, Shinya Kajiura, Yuko Ueda, Kohei Ogawa, Kenichiro Tsukada, Akira Ueda, Naokatsu Nakada, Ayumu Hosokawa, Tsutomu Fujii, Ichiro Yasuda
Journal: Annals of Oncology (2022)
MO44-5 The clinical outcome of patients with oligometastatic non-small cell lung cancer treated with first-line immunotherapy
Authors: Taichi Miyawaki, Hirotsugu Kenmotsu, Kousei Doushita, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi
Journal: Annals of Oncology (2022)
P31-4 Differentiated omental-derived adipose stem cells-conditioned medium promotes ovarian cancer migration and angiogenesis
Authors: Su chin Tham, Terence You De Cheng, Kah Yee Goh, Kah Weng Lau, Darren Wan-Teck Lim, Elaine Hsuen Lim
Journal: Annals of Oncology (2022)
Contraception in Women With Cardiovascular Disease
Authors: Kathryn J. Lindley, Stephanie B. Teal
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ann Robinson’s research reviews—21 July 2022
Authors: Ann Robinson
Journal: BMJ (2022)

<h3>Objective:</h3> Dysfunction of the default mode network (DMN) has been identified in prior cross-sectional fMRI studies of Alzheimer disease (AD) and mild cognitive impairment (MCI); however, no studies have examined its utility in predicting future cognitive decline. <h3>Methods:</h3> fMRI scans during a face–name memory task were acquired from a cohort of 68 subjects (25 normal control, 31 MCI, and 12 AD). Subjects with MCI were followed for 2.4 years (±0.8) to determine progression to AD. Maps of DMN connectivity were compared with a template DMN map constructed from elderly normal controls to obtain goodness-of-fit (GOF) indices of DMN expression. Indices were compared between groups and correlated with cognitive decline. <h3>Results:</h3> GOF indices were highest in normal controls, intermediate in MCI, and lowest in AD (<i>p</i> &lt; 0.0001). In a predictive model (that included baseline GOF indices, age, education, Mini-Mental State Examination score, and an index of DMN gray matter volume), the effect of GOF index on progression from MCI to dementia was significant. In MCI, baseline GOF indices were correlated with change from baseline in functional status (Clinical Dementia Rating–sum of boxes) (<i>r</i> = −0.40, <i>p</i> &lt; 0.04). However, there was no additional predictive value for DMN connectivity when baseline delayed recall was included in the models. <h3>Conclusions:</h3> fMRI connectivity indices distinguish patients with MCI who undergo cognitive decline and conversion to AD from those who remain stable over a 2- to 3-year follow-up period. Our data support the notion of different functional brain connectivity endophenotypes for “early” vs “late” MCI, which are associated with different baseline memory scores and different rates of progression and conversion.
Assessing the clinical utility of protein structural analysis in genomic variant classification: experiences from a diagnostic laboratory
Authors: Richard C. Caswell, Adam C. Gunning, Martina M. Owens, Sian Ellard, Caroline F. Wright
Journal: Genome Medicine (2022)

The widespread clinical application of genome-wide sequencing has resulted in many new diagnoses for rare genetic conditions, but testing regularly identifies variants of uncertain significance (VUS). The remarkable rise in the amount of genomic data has been paralleled by a rise in the number of protein structures that are now publicly available, which may have clinical utility for the interpretation of missense and in-frame insertions or deletions. Within a UK National Health Service genomic medicine diagnostic laboratory, we investigated the number of VUS over a 5-year period that were evaluated using protein structural analysis and how often this analysis aided variant classification. We found 99 novel missense and in-frame variants across 67 genes that were initially classified as VUS by our diagnostic laboratory using standard variant classification guidelines and for which further analysis of protein structure was requested. Evidence from protein structural analysis was used in the re-assessment of 64 variants, of which 47 were subsequently reclassified as pathogenic or likely pathogenic and 17 remained as VUS. We identified several case studies where protein structural analysis aided variant interpretation by predicting disease mechanisms that were consistent with the observed phenotypes, including loss-of-function through thermodynamic destabilisation or disruption of ligand binding, and gain-of-function through de-repression or escape from proteasomal degradation. We have shown that using in silico protein structural analysis can aid classification of VUS and give insights into the mechanisms of pathogenicity. Based on our experience, we propose a generic evidence-based workflow for incorporating protein structural information into diagnostic practice to facilitate variant classification.
Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection
Authors: Young-Eun Kim, Kyungmin Huh, Young-Joon Park, Kyong Ran Peck, Jaehun Jung
Journal: JAMA (2022)

Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza
Importance of a Balanced Public Health Approach When Assessing Recent Patterns in the Prevalence of Adult e-Cigarette Use in the US
Authors: Julia Chen-Sankey, Michelle T. Bover-Manderski
Journal: JAMA Network Open (2022)

Ellen Boakye, MD, MPH; Ngozi Osuji, MD, MPH; John Erhabor, MD, MPH; Olufunmilayo Obisesan, MD, MPH; Albert D. Osei, MD, MPH; Mohammadhassan Mirbolouk, MD; Andrew C. Stokes, PhD; Omar Dzaye, MD, MPH, PhD; Omar El Shahawy, MD, MPH, PhD; Glenn A. Hirsch, MD, MHS; Emelia J. Benjamin, MD, ScM; Andrew P. DeFilippis, MD, MSc; Rose Marie Robertson, MD; Aruni Bhatnagar, PhD; Michael J. Blaha, MD, MPH
Use of Electronic Cigarettes Among Cannabis-Naive Adolescents and Its Association With Future Cannabis Use
Authors: Ruoyan Sun, David Mendez, Kenneth E. Warner
Journal: JAMA Network Open (2022)

Electronic cigarette (e-cigarette) use has been reported to increase the likelihood of future cigarette smoking among adolescents. The prospective association between e-cigarette use and cannabis use has been less clear, especially in recent years.To examine the association between e-cigarette use among cannabis-naive adolescents and cannabis use 1 year later.The Population Assessment of Tobacco and Health (PATH) Study, a nationally representative cohort study, uses a 4-stage, stratified probability sample design to select participants aged 12 years or older from the US civilian, noninstitutionalized population. This study sample included 9828 cannabis-naive adolescents at the baseline survey who participated in both wave 4.5 (2017-2018) and wave 5 (2018-2019) of PATH.e-Cigarette use, assessed by ever use, past 12-month use, and past 30-day use.Cannabis use in wave 5, assessed by past 12-month and past 30-day use. Multivariable logistic regressions assessed the association between e-cigarette use and cannabis use 1 year later. Results were weighted to produce nationally representative findings.Of the 9828 adolescents included in the analysis, 5361 (57.3%) were aged 12 to 14 years, 5056 (50.7%) were male, and 4481 (53.0%) were non-Hispanic White. After adjustment for sociodemographic characteristics, environmental factors, other substance use, and sensation seeking, e-cigarette use among cannabis-naive adolescents was associated with increased likelihoods of both self-reported past 12-month and past 30-day cannabis use 1 year later. The adjusted relative risks (aRRs) of subsequent past 12-month cannabis use with ever use of e-cigarettes was 2.57 (95% CI, 2.04-3.09), with past 12-month use of e-cigarettes was 2.62 (95% CI, 2.10-3.15), and with past 30-day use of e-cigarettes was 2.18 (95% CI, 1.50-2.85). The aRRs of subsequent past 30-day cannabis use with ever use of e-cigarettes was 3.20 (95% CI, 2.10-4.31), with past 12-month use of e-cigarettes was 3.40 (95% CI, 2.17-4.63), and with past 30-day use of e-cigarettes was 2.96 (95% CI, 1.52-4.40).This cohort study's findings suggest a strong association between adolescent e-cigarette use and subsequent cannabis use. However, despite the strong association at the individual level, e-cigarette use seems to have had a minimal association with the prevalence of youth cannabis use at the population level.
Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016
Authors: Andrew F Brouwer, Jason M Engle, Jihyoun Jeon, Rafael Meza
Journal: JNCI Journal of the National Cancer Institute (2022)

Abstract Background Understanding the impact of patient and tumor characteristics on lung cancer survival can help build personalized prognostic models and identify health disparities. Methods We identified 557 555 patients aged 25 years and older diagnosed with lung or bronchus carcinoma from the Surveillance, Epidemiology, and End Results database, 2000-2016. We estimated hazard ratios (HR) for demographic (sex, age, race and ethnicity), tumor (stage, histology, year of diagnosis), and geographic characteristics (census tract–level urbanicity, socioeconomic status [SES]), as well as selected interactions, on the rate of lung cancer–specific death using multivariable proportional hazards models. Results Women had a higher survival (lower hazard) of lung cancer–specific death than men (HR = 0.83, 95% confidence interval [CI] = 0.82 to 0.83). Hazards differed by race and ethnicity. Regional (HR = 2.41, 95% CI = 2.37 to 2.44) and distant (HR = 6.61, 95% CI = 6.53 to 6.69) tumors were associated with a lower survival (higher hazard) than localized tumors. Small cell tumors were associated with a lower survival (HR = 1.19, 95% CI = 1.18 to 1.20) than non–small cell tumors. Patients diagnosed after 2009 had lower hazards (HR = 0.86, 95% CI = 085 to 0.86) than those diagnosed 2000-2009. Lung cancer–specific survival did not depend on urbanicity after adjusting for census tract–level SES, but survival decreased with decreasing census tract–level SES. Differences in survival between non-Hispanic Black and White patients were greater for younger patients and localized tumors and increased with census tract–level SES. Differences by sex were greatest for young patients and localized tumors. Conclusions Disparities in survival after lung cancer diagnosis remain, with intersectional patterns suggesting differential access to and quality of care. Efforts are needed to ensure that high-risk groups receive guideline-concordant treatment.
Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort
Authors: Neehar D. Parikh, Nabihah Tayob, Taim Al-Jarrah, Jennifer Kramer, Jennifer Melcher, Donna Smith, Patrick Marquardt, Po-Hong Liu, Runlong Tang, Fasiha Kanwal, Amit G. Singal
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Hepatocellular carcinoma (HCC) surveillance is underused in clinical practice, which may be owing to patient and clinician barriers. <h3>Objective</h3> To characterize HCC surveillance barriers and associations with clinical outcomes in a multicenter cohort of patients with cirrhosis. <h3>Design, Setting, and Participants</h3> This retrospective, multicenter cohort study included 5 medical centers in the United States. Patients with cirrhosis and newly diagnosed HCC treated from 2014 to 2018 were included. Data were analyzed from June 2021 to February 2022. <h3>Exposure</h3> Surveillance completion in the 36-month period prior to HCC diagnosis. <h3>Main Outcomes and Measures</h3> Surveillance receipt was classified as semiannual, annual, or no surveillance. Multivariable logistic regression analysis was used to identify factors associated with semiannual surveillance. We conducted multivariable logistic and Cox regression analyses to characterize associations between surveillance completion with curative treatment and overall survival. <h3>Results</h3> A total 629 eligible patients (median [IQR] age, 63.6 [56.2-71.0] years; 491 [78.1%] men) were assessed, including 7 American Indian or Alaska Native patients (1.1%), 14 Asian patients (2.2), 176 Black patients (28.0%), 86 Hispanic patients (13.1%), and 340 White patients (54.1%). Nearly two-thirds of the cohort had no surveillance prior to HCC diagnosis (mean [range by site] 63.7% [37.9%-80.4%]), with a mean (range by site) of 14.0% (5.3%-33.3%) of patients having received semiannual surveillance and 22.3% (14.3%-28.8%) of patients having received annual surveillance. The most common reasons for no surveillance were lack of surveillance orders or nonadherence (mean [range by site], 82.4% [66.7%-92.4%], although a mean (range by site) of 17.6% (10.2%-22.1%) of patients had unrecognized cirrhosis at HCC presentation. Semiannual surveillance was associated with hepatitis B infection (odds ratio [OR], 3.06 [95% CI, 1.24-7.23]) and inversely associated with Black race (OR, 0.41 [95% CI, 0.20-0.80]) and lack of cirrhosis recognition (OR, 0.14 [95% CI, 0.02-0.46]). Semiannual HCC surveillance was significantly associated with curative treatment receipt (OR, 2.73 [95% CI, 1.60-4.70]) but not overall survival (HR, 0.81 [95% CI, 0.55-1.18]). <h3>Conclusions and Relevance</h3> In this cohort study of patients with cirrhosis, HCC surveillance was underused in more than 80% of patients and associated with failures across the screening process. Dedicated programs to improve cirrhosis detection and HCC surveillance attainment are needed.
Analysis of Radiology Report Recommendation Characteristics and Rate of Recommended Action Performance
Authors: Tiantian White, Mark D. Aronson, Scot B. Sternberg, Umber Shafiq, Seth J. Berkowitz, James Benneyan, Russell S. Phillips, Gordon D. Schiff
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Following up on recommendations from radiologic findings is important for patient care, but frequently there are failures to carry out these recommendations. The lack of reliable systems to characterize and track completion of actionable radiology report recommendations poses an important patient safety challenge. <h3>Objectives</h3> To characterize actionable radiology recommendations and, using this taxonomy, track and understand rates of loop closure for radiology recommendations in a primary care setting. <h3>Design, Setting, and Participants</h3> Radiology reports in a primary care clinic at a large academic center were redesigned to include actionable recommendations in a separate dedicated field. Manual review of all reports generated from imaging tests ordered between January 1 and December 31, 2018, by primary care physicians that contained actionable recommendations was performed. For this quality improvement study, a taxonomy system that conceptualized recommendations was developed based on 3 domains: (1) what is recommended (eg, repeat a test or perform a different test, specialty referral), (2) specified time frame in which to perform the recommended action, and (3) contingency language qualifying the recommendation. Using this framework, a 2-stage process was used to review patients' records to classify recommendations and determine loop closure rates and factors associated with failure to complete recommended actions. Data analysis was conducted from April to July 2021. <h3>Main Outcomes and Measures</h3> Radiology recommendations, time frames, and contingencies. Rates of carrying out vs not closing the loop on these recommendations in the recommended time frame were assessed. <h3>Results</h3> A total of 598 radiology reports were identified with structured recommendations: 462 for additional or future radiologic studies and 196 for nonradiologic actions (119 specialty referrals, 47 invasive procedures, and 43 other actions). The overall rate of completed actions (loop closure) within the recommended time frame was 87.4%, with 31 open loop cases rated by quality expert reviewers to pose substantial clinical risks. Factors associated with successful loop closure included (1) absence of accompanying contingency language, (2) shorter recommended time frames, and (3) evidence of direct radiologist communication with the ordering primary care physicians. A clinically significant lack of loop closure was found in approximately 5% of cases. <h3>Conclusions and Relevance</h3> The findings of this study suggest that creating structured radiology reports featuring a dedicated recommendations field permits the development of taxonomy to classify such recommendations and determine whether they were carried out. The lack of loop closure suggests the need for more reliable systems.